RxDoctor Payments DataLook up a doctor →

Ian Herskowitz, MD

Endocrinology, Diabetes & Metabolism · Augusta, GANPI 1295880680

Payments from drug & device makers

$18,879in general payments, 2019–2025

Across 989 payments — averaging $19.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$2K
  • Novo Nordisk$2K
  • Sanofi-aventis U.S. LLC$1K
  • Corcept Therapeutics$1K
  • Amgen$1K
  • Medtronic$1K
  • plus $11K from 51 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lilly USA, LLC91$1,584
Novo Nordisk100$1,541
Sanofi-aventis U.S. LLC75$1,482
Corcept Therapeutics44$1,117
Amgen(2 entities)50$1,055
Medtronic(2 entities)35$1,047
Bayer41$976
Boehringer Ingelheim51$884
AstraZeneca(2 entities)46$763
AbbVie38$641
Mannkind Corporation30$614
Antares Pharma, Inc.38$583
Xeris Pharmaceuticals, Inc.30$568
Dexcom, Inc.34$561
Tandem Diabetes Care, Inc.27$550
Abbott31$526
IBSA Pharma Inc.25$498
Insulet Corporation30$446
Merck28$427
Novartis12$215
BETA Bionics, Inc.3$205
Amneal Pharmaceuticals LLC10$189
Zealand Pharma US, Inc.10$172
Johnson & Johnson9$160
Cequr Corporation4$155
Takeda Pharmaceuticals U.S.A., Inc.1$125
Ultragenyx Pharmaceutical Inc.5$122
Ascendis Pharma Endocrinology Inc6$115
Amarin Pharma, Inc.6$103
BD6$101
Radius Health, Inc.5$100
Halozyme Inc6$99
Sunovion Pharmaceuticals Inc.12$98
Lifescan, Inc.5$82
Shire North American Group Inc5$82
Clarus Therapeutics Inc.7$81
Senseonics, Incorporated1$78
Kyowa Kirin, Inc.3$73
Amryt Pharma Holdings Ltd4$69
Madrigal Pharmaceuticals2$67
Nevro Corp.1$57
Ascensia Diabetes Care US Inc.2$46
Sequel Med Tech, LLC2$45
Acella Pharmaceuticals, LLC1$43
Recordati_rare_diseases_inc.2$40
GSK2$39
Neurocrine Biosciences, Inc.1$37
Endo Pharmaceuticals Inc.2$34
Boston Scientific2$31
Sanofi US Services Inc.1$26
Roche Diabetes Care, Inc.1$24
Embecta Corp.1$22
EUSA Pharma (US) LLC1$22
Biohaven Pharmaceuticals, Inc.1$20
Astellas Pharma US Inc1$14
Supernus Pharmaceuticals, Inc.1$13
Currax Pharmaceuticals LLC1$12

How this compares

$18,879 in reported general payments places this provider in the 85th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.

See all endocrinology, diabetes & metabolism providers in Georgia →

Medicare billing

Part B allowed, 2024
$132,017
Medicare patients
660
Services billed
3,139

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Augusta

See the full list for Georgia →

Where these figures come from

Is this you, or does something look wrong? →